Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02782975 · ClinicalTrials.gov registry record · Phase 1
Absolute Bioavailability of a Single, Fixed Subcutaneous Dose of Aducanumab in Healthy Participants
A Phase 1 study, sponsored by Biogen.
- Completed
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT02782975 is a Phase 1 study that has completed, run by Biogen. The registered enrollment target is 28 participants.
The verdict
NCT02782975, a Phase 1 study, has completed, sponsored by Biogen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
The primary objectives of this study are to evaluate the absolute bioavailability of a single, fixed sub-cutaneous (SC) dose of aducanumab compared with a single, weight-based intra-venous (IV) dose in healthy participants and to characterize the pharmacokinetics (PK) profile of aducanumab. The secondary objectives are to evaluate the safety and tolerability of aducanumab administered via SC and IV routes in healthy participants and to characterize additional PK parameters of a single, fixed SC dose of aducanumab and a weight-based IV dose in healthy participants.
Interventions
- DRUG aducanumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2016-05 |
| Est. Completion | 2016-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02782975
The ClinicalTrials.gov registry entry for NCT02782975 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which aducanumab is the first listed.
NCT02782975 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02782975 about?
NCT02782975 is a clinical study titled "Absolute Bioavailability of a Single, Fixed Subcutaneous Dose of Aducanumab in Healthy Participants". The primary objectives of this study are to evaluate the absolute bioavailability of a single, fixed sub-cutaneous (SC) dose of aducanumab compared with a single, weight-based intra-venous (IV) dose in healthy participants and to characterize the pharmacokinetics (PK) profile of aducanumab. The seco...
What is the current status of trial NCT02782975?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2016-05. Estimated completion is 2016-11.
What interventions are being tested in trial NCT02782975?
The interventions under investigation include: aducanumab (DRUG).
Who is sponsoring clinical trial NCT02782975?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.